Ceftazidime-avibactam in ceftazidime-resistant infections

Affiliations

¹ Division of Epidemiology and the National Center for Antibiotic Resistance and Infection Control, Tel Aviv Sourasky Medical Center, Tel Aviv, 64239, Israel. Electronic address: yehudac@tlvmc.gov.il.
² AstraZeneca, Infection GMed, Global Medicines Development, Alderley Park, Macclesfield, UK.
³ AstraZeneca, Infection GMed, Global Medicines Development, Waltham, MA, USA.

Comment

Yehuda Carmeli et al. Lancet Infect Dis. 2016 Sep.

. 2016 Sep;16(9):997-998.

doi: 10.1016/S1473-3099(16)30265-1.

¹ Division of Epidemiology and the National Center for Antibiotic Resistance and Infection Control, Tel Aviv Sourasky Medical Center, Tel Aviv, 64239, Israel. Electronic address: yehudac@tlvmc.gov.il.
² AstraZeneca, Infection GMed, Global Medicines Development, Alderley Park, Macclesfield, UK.
³ AstraZeneca, Infection GMed, Global Medicines Development, Waltham, MA, USA.

No abstract available

Comment on

Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study.
Carmeli Y, Armstrong J, Laud PJ, Newell P, Stone G, Wardman A, Gasink LB. Carmeli Y, et al. Lancet Infect Dis. 2016 Jun;16(6):661-673. doi: 10.1016/S1473-3099(16)30004-4. Epub 2016 Apr 20. Lancet Infect Dis. 2016. PMID: 27107460 Clinical Trial.
Ceftazidime-avibactam in ceftazidime-resistant infections.
Raut S, Adhikari B. Raut S, et al. Lancet Infect Dis. 2016 Sep;16(9):997. doi: 10.1016/S1473-3099(16)30194-3. Lancet Infect Dis. 2016. PMID: 27684335 No abstract available.